Vision Mission & Strength
Quality Policy
Manufacturing Facility
R & D
Management Messages
Business Motto
Doxiva Montiva
Bexen Cefracef Fixpro Nixon Xinarox Xinarox CV
Metavas MR Nitrogina SR
Tamino ER Tamino Plus
Vermikil
Florocin Revalon Toplevo 500
Carceva 75 Carceva plus
Azaltic
Diacana Diazid Empa EmpaMet Glucomin Lijenta 5 Lijenta-M Lijenta-MX
Receca
Anxionil Lyrinex Pandura Thixtra
AMX Halopen
Flurodent
Mesala Mevigut SR
Fluvigan 200
Altrip
Nitide
Adarbi Bisopress Losarva Losarva Plus Lovapres 5
Mecliz Plus Prokinet
Defungi Fenticona Symbiotrin
Meroxin
Bactropen
Esotor Omecron Pansos Rablet
Arcet Bilfast Fexten Itchlor Rupatid
Visnil
Isosal
Broculyt Erdostin Mucodil Nacsol
Irobest
Avamist Oxydrop
Etrib Flexivan Flexivan ER Nimovo Nipoxen Toralin Vurdon SR
Niprolac Oral Sol
D-Star Nipro Gold Nipro Seas Oxi-Q Polytamin Starcal Starcal D Starcal M V3N V4Z Vegecap-E
Avator Rovator
Reflexen
Cialix Danafil
NIPRO JMI Pharma successfully produced Favipiravir in the name of Fluvigan Tablets (Favipiravir 200 mg) for the treatment of COVID -19 patients....
NIPRO JMI Pharma held Annual Sales Conference 2019 on 2nd January ( Thursday ), at Bangabandhu International Conference Center (BICC), in Dhaka. Managing Director of this company Mr Abdur Razzaq inaugurate the program. Chairman of NIPRO JMI Pharma Mr Jabed Iqbal Pathan,CEO Md Mizanur Rahman & about 1600 marketing force attend this conference...
Noted Medicine Specialist Professor Dr Md Billal Alam, Principal and head of the Department of Medicine, Sir Salimullah Medical College, Dhaka and President of Bangladesh Society of Medicine and Gynacologist Dr Feroza Wazed, Associate Professor, Dept. of Obstetrics and Gynacology, Dhaka Medical College and Hospital
NIPRO JMI Pharma Ltd. (NJP) is contributing in developing a world-class practicein the pharma industry of Bangladesh by bridling the unment challenges in healthcare sector. It is one of the fastest growing pharmaceutical companies in Bangladesh, started its journey in 2012 with collaboration of NIPRO Corporation; a Japan based giant multinational company, a press release said.
Prescribing Information
Bilastine is a non-sedating, long-acting histamine antagonist with selective peripheral H1 receptor antagonist affinity and no affinity for muscarinic receptors. Bilastine inhibits histamine-induced wheal and flare skin reactions for 24 hours following single doses.